NCT06681870 2025-01-15
A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors
Astellas Pharma Inc
Phase 1 Withdrawn
Clinical Trials
24 trialsNCT06161493 2024-10-15
ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors
University of Pittsburgh
Phase 1 Withdrawn
NCT06216561 2024-08-20
Intraperitoneal LSTA1 in CRS-HIPEC
University of California, San Diego
Phase 1 Withdrawn
NCT04542603 2024-04-25
Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian Cancer
University of Alabama at Birmingham
Phase 1 Withdrawn
NCT04602117 2023-11-18
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
QuantumLeap Healthcare Collaborative
Phase 1 Withdrawn
NCT05905341 2023-11-08
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
Pfizer
Phase 1 Withdrawn
NCT05431582 2023-06-15
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT04149145 2023-06-07
PARP
University of Alabama at Birmingham
Phase 1 Withdrawn
NCT02117817 2022-07-28
Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer
Rutgers, The State University of New Jersey
Phase 1 Withdrawn
NCT04941378 2022-06-27
OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Withdrawn
NCT03400306 2021-12-08
A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer
AbbVie
Phase 1 Withdrawn
NCT04498520 2021-05-18
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
University of California, San Francisco
Phase 1 Withdrawn
NCT03644459 2020-03-11
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101
Lynkcell Inc.
Phase 1 Withdrawn
NCT02833506 2018-05-01
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Roswell Park Cancer Institute
Phase 1 Withdrawn
NCT01386502 2017-07-02
CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT02567396 2017-04-24
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT01138137 2017-04-21
N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer
OHSU Knight Cancer Institute
Phase 1 Withdrawn
NCT00842582 2016-11-02
Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer
Loyola University
Phase 1 Withdrawn
NCT02083536 2016-08-10
LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma
University of Miami
Phase 1 Withdrawn
NCT02470559 2016-02-17
Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent
Barbara Ann Karmanos Cancer Institute
Phase 1 Withdrawn
NCT00659399 2015-03-18
Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression
NYU Langone Health
Phase 1 Withdrawn
NCT00017537 2013-08-05
Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer
University of Alabama at Birmingham
Phase 1 Withdrawn
NCT00942838 2013-07-24
WAR
University of Utah
Phase 1 Withdrawn
NCT00118300 2011-07-08
Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer
Case Comprehensive Cancer Center
Phase 1 Withdrawn